Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jul;109(1):170-7.
doi: 10.1016/j.diabres.2015.04.013. Epub 2015 Apr 23.

Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort

J A Black  1 , G H Long  1 , S J Sharp  1 , L Kuznetsov  1 , C E Boothby  1 , S J Griffin  2 , R K Simmons  3
Affiliations
Randomized Controlled Trial

Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort

J A Black et al. Diabetes Res Clin Pract. 2015 Jul.

Abstract

Aims: Establishing a balance between the benefits and harms of treatment is important among individuals with screen-detected diabetes, for whom the burden of treatment might be higher than the burden of the disease. We described the association between cardio-protective medication and health-related quality of life (HRQoL) among individuals with screen-detected diabetes.

Methods: 867 participants with screen-detected diabetes underwent clinical measurements at diagnosis, one and five years. General HRQoL (EQ5D) was measured at baseline, one- and five-years, and diabetes-specific HRQoL (ADDQoL-AWI) and health status (SF-36) at one and five years. Multivariable linear regression was used to quantify the association between change in HRQoL and change in cardio-protective medication.

Results: The median (IQR) number of prescribed cardio-protective agents was 2 (1 to 3) at diagnosis, 3 (2 to 4) at one year and 4 (3 to 5) at five years. Change in cardio-protective medication was not associated with change in HRQoL from diagnosis to one year. From one year to five years, change in cardio-protective agents was not associated with change in the SF-36 mental health score. One additional agent was associated with an increase in the SF-36 physical health score (2.1; 95%CI 0.4, 3.8) and an increase in the EQ-5D (0.05; 95%CI 0.02, 0.08). Conversely, one additional agent was associated with a decrease in the ADDQoL-AWI (-0.32; 95%CI -0.51, -0.13), compared to no change.

Conclusions: We found little evidence that increases in the number of cardio-protective medications impacted negatively on HRQoL among individuals with screen-detected diabetes over five years.

Keywords: Diabetes; HRQoL; Medication.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of change in quality of life measures by change in cardio-protective agents in ADDITION-Cambridge cohort. Δ = Change; SF-36 MCS = SF36 mental health summary score; SF-36 PCS = SF36 physical health summary score; ADDQoL-AWI = Audit of diabetes-dependent quality of life average weighted index.
See this image and copyright information in PMC

References

    1. Zimmet P., Alberti K.G.M.M., Shaw J.E. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787. - PubMed
    1. Wexler D.J., Grant R.W., Wittenberg E. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49:1489–1497. - PubMed
    1. Holman R.R., Paul S.K., Bethel M.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. - PubMed
    1. Huang E.S., Brown S.E.S., Ewigman B.G. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30:2478–2483. - PMC - PubMed
    1. Grant R.W., Devita N.G., Singer D.E., Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–1412. - PubMed

Publication types

MeSH terms

Substances